In a recent filing, it was disclosed that Ezra Uzi Yemin, serving as a director for Delek US Holdings, Inc. (NYSE: DK), disposed of 34,026 shares of the company's common stock. The transaction took place on May 4, 2026, and resulted in total proceeds of roughly $1,609,089.
The sale was executed at various price points between $47.00 and $47.93 per share, which brought the weighted average selling price to $47.29. This specific transaction was not a direct personal trade but was carried out indirectly through Yemin Investments, LP. Furthermore, the sale was conducted in accordance with a pre-arranged 10b5-1 trading plan, a mechanism often used by corporate insiders to schedule trades in advance.
Current Market Position and Valuation
The timing of this insider sale follows a period of intense upward momentum for Delek US shares. Over the course of the last year, the stock has surged by 236%, while its year-to-date performance shows a gain of 54%. Despite these gains, the stock was trading at $45 following the recent activity. According to analysis from InvestingPro, the equity is currently considered undervalued relative to its Fair Value, placing it on a list of the most undervalued stocks available on the platform.
Following this divestment, Mr. Yemin maintains a significant position in the company. Through Yemin Investments, LP, he indirectly holds 447,795 shares of Delek US Holdings common stock, while also maintaining a direct holding of 210,281 shares.
Recent Financial Performance and Analyst Outlook
The insider activity occurs alongside a recent release of Q1 2026 earnings, which presented a multifaceted financial picture for Delek US Holdings Inc. The company reported a loss per share of $0.98, a figure that was higher than the anticipated $0.83 loss. However, this loss was offset by strong top-line performance; revenue reached $2.65 billion, significantly outperforming the projected $2.33 billion.
Wall Street analysts have responded to these developments with improved price targets. Goldman Sachs has maintained a Buy rating on the stock, raising its price target to $57. Analyst Alexa Petrick noted that Delek US possesses an attractive risk-reward profile, supported by steady contributions and cost-reduction efforts. Similarly, Raymond James lifted its price target to $59, citing a strong macroeconomic environment for U.S. refiners and operational improvements within the company.
Key Market Points
- Insider Divestment: The sale of over 34,000 shares by a director via a 10b5-1 plan provides insight into internal liquidity management.
- Revenue Strength vs. Earnings Miss: Delek US demonstrated an ability to exceed revenue expectations despite reporting a larger-than-expected loss per share in Q1 2026.
- Sector Dynamics: Analyst commentary suggests that the broader macroeconomic backdrop for U.S. refiners is currently contributing to positive outlooks for companies like Delek US.
Risks and Uncertainties
- Earnings Volatility: The discrepancy between the projected $0.83 loss and the actual $0.98 loss per share highlights potential uncertainty in near-term profitability.
- Valuation Discrepancies: While some analysts have raised price targets, the stock's recent performance must be weighed against its reported quarterly losses.